BR112012022946A2 - método para proliferar cardiomiócitos usando micro-rna - Google Patents

método para proliferar cardiomiócitos usando micro-rna

Info

Publication number
BR112012022946A2
BR112012022946A2 BR112012022946A BR112012022946A BR112012022946A2 BR 112012022946 A2 BR112012022946 A2 BR 112012022946A2 BR 112012022946 A BR112012022946 A BR 112012022946A BR 112012022946 A BR112012022946 A BR 112012022946A BR 112012022946 A2 BR112012022946 A2 BR 112012022946A2
Authority
BR
Brazil
Prior art keywords
mir
rna
micro
proliferating cardiomyocytes
vector
Prior art date
Application number
BR112012022946A
Other languages
English (en)
Inventor
Kawashima Kayoko
Koshimizu Uichi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112012022946A2 publication Critical patent/BR112012022946A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Abstract

método para proliferar cardiomiócitos usando micro-rna. a presente invenção refere-se a um método para proliferar cardiomiócitos, em que um mirna que promove a proliferação de cardiomiócitos é usado: um vetor para o tratamento de doenças cardíacas. a presente invenção refere-se a um método para proliferar cardiomiócitos, que usa um mirna que tem a ação promotora de proliferação de cardiomiócitos: um vetor para o tratamento de doenças cardíacas, que compreende o mirna; e uma composição farmacêutica, ou similar, para o tratamento de doenças cardíacas, que contém o vetor. o mirna é preferivelmente um selecionado do grupo que consiste em mir-148a, mir-148b, mir-152, mir-373 que são mirnas maduros, precursores dos mirnas acima mencionados, e mutantes e análogos dos mirnas e os precusores.
BR112012022946A 2010-03-12 2011-03-11 método para proliferar cardiomiócitos usando micro-rna BR112012022946A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010056558 2010-03-12
PCT/JP2011/055789 WO2011111824A1 (ja) 2010-03-12 2011-03-11 マイクロrnaを用いた心筋細胞の増殖方法

Publications (1)

Publication Number Publication Date
BR112012022946A2 true BR112012022946A2 (pt) 2017-02-07

Family

ID=44563622

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022946A BR112012022946A2 (pt) 2010-03-12 2011-03-11 método para proliferar cardiomiócitos usando micro-rna

Country Status (11)

Country Link
US (3) US20130005796A1 (pt)
EP (2) EP2842577A1 (pt)
JP (1) JPWO2011111824A1 (pt)
KR (1) KR20130008560A (pt)
CN (1) CN102858376A (pt)
AU (2) AU2011225115B2 (pt)
BR (1) BR112012022946A2 (pt)
CA (1) CA2792411A1 (pt)
RU (1) RU2012143607A (pt)
SG (2) SG10201501610VA (pt)
WO (1) WO2011111824A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
CN103446593A (zh) * 2013-08-19 2013-12-18 南京市妇幼保健院 人miR-148a在制备促进脂肪细胞分化药物中的应用
GB201806569D0 (en) * 2018-04-23 2018-06-06 Univ Edinburgh Method of treatment
KR102071302B1 (ko) 2018-06-28 2020-01-30 한국과학기술연구원 엑소좀 기반의 심근세포 교차분화 유도방법
CN110907644B (zh) * 2019-12-11 2023-01-06 深圳市达科为生物工程有限公司 多种细胞鉴定试剂盒及操作方法
EP3936616A1 (en) 2020-07-10 2022-01-12 Charité - Universitätsmedizin Berlin Microrna-targeted therapy for cardiac repair
CN111956658B (zh) * 2020-07-28 2023-04-28 中国医学科学院医药生物技术研究所 miRNA 148簇作为诊断和/或治疗认知障碍相关疾病标志物的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015671A (en) 1995-06-07 2000-01-18 Indiana University Foundation Myocardial grafts and cellular compositions
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
AU784618B2 (en) 1999-12-28 2006-05-18 Kyowa Hakko Kogyo Co. Ltd. Cells capable of differentiating into heart muscle cells
CA2453438C (en) 2001-07-12 2016-04-05 Geron Corporation Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
EP1306198A1 (de) 2001-10-24 2003-05-02 Verein PRS PET-Recycling Schweiz Verfahren zur Sammlung leerer Kunststoff-Behälter sowie Presse zu dessen Durchführung
US20070009496A1 (en) * 2003-11-21 2007-01-11 Daiichi Asubio Pharma Co., Ltd. Method of growing myocardial cells
US8592384B2 (en) 2005-04-04 2013-11-26 The Board Of Regents Of The University Of Texas System Micro-RNA's that regulate muscle cells
JP2008538504A (ja) * 2005-04-21 2008-10-30 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｈｉｖ感染を阻害する方法および組成物
WO2007112001A2 (en) * 2006-03-23 2007-10-04 Caritas St. Elizabeth Medical Center Of Boston, Inc. Compositions and methods for treating myocardial infarction
EP2117582B1 (en) * 2007-01-22 2013-06-26 Children's Medical Center Corporation Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration
KR20100099158A (ko) 2007-11-09 2010-09-10 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ
US20110054012A1 (en) * 2007-12-28 2011-03-03 Place Robert F Methods and Compositions for Increasing Gene Expression
WO2009092005A2 (en) * 2008-01-18 2009-07-23 The J. David Gladstone Institutes Methods of generating cardiomyocytes and cardiac progenitors and compositions
US8258111B2 (en) * 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US20110201103A1 (en) * 2008-08-07 2011-08-18 University Of Southern California System For Synergetic Expression Of Multiple Small Functional RNA Elements
WO2010135570A1 (en) * 2009-05-20 2010-11-25 Board Of Regents, The University Of Texas System Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure
EP2305810A1 (en) * 2009-10-02 2011-04-06 Technische Universität München miRNAs in the treatment of fibrosis
WO2011133288A1 (en) * 2010-04-19 2011-10-27 The Trustees Of The University Of Pennsylvania Microrna induction of pluripotential stem cells and uses thereof
US20130150256A1 (en) * 2010-06-11 2013-06-13 Jane Synnergren Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types

Also Published As

Publication number Publication date
SG10201501610VA (en) 2015-04-29
US20140213633A1 (en) 2014-07-31
AU2011225115A1 (en) 2012-10-25
CN102858376A (zh) 2013-01-02
US20130005796A1 (en) 2013-01-03
EP2545941A4 (en) 2013-10-23
AU2011225115B2 (en) 2014-10-23
CA2792411A1 (en) 2011-09-15
US20140213634A1 (en) 2014-07-31
SG184026A1 (en) 2012-10-30
WO2011111824A1 (ja) 2011-09-15
JPWO2011111824A1 (ja) 2013-06-27
EP2842577A1 (en) 2015-03-04
AU2014224131A1 (en) 2014-10-02
RU2012143607A (ru) 2014-04-20
KR20130008560A (ko) 2013-01-22
EP2545941A1 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
BR112012022946A2 (pt) método para proliferar cardiomiócitos usando micro-rna
BR112012027509A8 (pt) Composto pirazolil-quinoxalina inibidor de quinase, combinação, produto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e método
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112017019409A2 (pt) forma cristalina de ribosídeo de nicotinamida
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
EA201590868A1 (ru) Противовирусные соединения
MD4496C1 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
GEP20166496B (en) Substituted nucleosides, nucleotides and analogs thereof
EA201890333A1 (ru) Противовирусные соединения
MX347596B (es) Derivados de purina para el tratamiento de infecciones viricas.
BR112017012927A2 (pt) partícula compósita, processo cosmético e métodos para a preparação de uma partícula compósita
BR112016021648A2 (pt) novos compostos
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
IN2015DN01151A (pt)
GEP20156231B (en) Agomelatine hydrochloride hydrate and preparation there of

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]